Emerging as a promising breakthrough in the fight against obesity, Retatrutide is capturing considerable buzz. It combines properties of two known GLP-1 receptor agonists, liraglutide, plus an unique glucose-dependent incretin component. Initial study data have demonstrated impressive fat decrease in patients with a high BMI , possibly providing a